NIAID supports the development of new and improved diagnostic tools for faster and more accurate diagnosis of early tuberculosis (TB) disease and Mycobacterium tuberculosis (Mtb) infection, to help optimize therapy by identifying drug-resistant strains, and to track the spread of TB in a community. The Institute also encourages researchers to develop tools and identify biomarkers that allow clinicians to rapidly assess how people respond to therapy and to assist in conducting drug and vaccine clinical trials.
Scientific Advances
World TB Day 2024 – ‘Yes! We Can End TB!’
March 22, 2024
Included in the World TB Day 2024 news release, information about how NIAID continues to support the evaluation of promising early-stage TB diagnostics and strategies through the Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) consortium.